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Abstract
Background: A fundamental problem in cancer research is identifying the cell type that is capable of sustaining neoplastic
growth and its origin from normal tissue cells. Recent investigations of a variety of tumor types have shown that
phenotypically identifiable and isolable subfractions of cells possess the tumor-forming ability. In the present paper, using
two lineage-related human melanoma cell lines, primary melanoma line IGR39 and its metastatic derivative line IGR37, two
main observations are reported. The first one is the first phenotypic evidence to support the origin of melanoma cancer
stem cells (CSCs) from mutated tissue-specific stem cells; and the second one is the identification of a more aggressive
subpopulation of CSCs in melanoma that are CXCR6+.
Methods/Findings: We defined CXCR6 as a new biomarker for tissue-specific stem cell asymmetric self-renewal. Thus, the
relationship between melanoma formation and ABCG2 and CXCR6 expression was investigated. Consistent with their non-
metastatic character, unsorted IGR39 cells formed significantly smaller tumors than unsorted IGR37 cells. In addition,
ABCG2+ cells produced tumors that had a 2-fold greater mass than tumors produced by unsorted cells or ABCG2- cells.
CXCR6+ cells produced more aggressive tumors. CXCR6 identifies a more discrete subpopulation of cultured human
melanoma cells with a more aggressive MCSC phenotype than cells selected on the basis of the ABCG2+ phenotype alone.
Conclusions/Significance: The association of a more aggressive tumor phenotype with asymmetric self-renewal phenotype
reveals a previously unrecognized aspect of tumor cell physiology. Namely, the retention of some tissue-specific stem cell
attributes, like the ability to asymmetrically self-renew, impacts the natural history of human tumor development.
Knowledge of this new aspect of tumor development and progression may provide new targets for cancer prevention and
treatment.
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Introduction
Cancer chemotherapy efficacy is frequently impaired by either
intrinsic or acquired tumor resistance, a phenomenon termed
multi-drug resistance (MDR) [1]. MDR can result from several
distinct mechanisms, including reducing drug accumulation in
tumor cells [1]. The mechanism that is most commonly
encountered in the laboratory is the increased efflux of a broad
class of hydrophobic cytotoxic drugs that is mediated by one of a
family of energy-dependent transporters (ABC family) [2].
Although several members of the superfamily have dedicated
particular functions involving the transport of specific substrates, it
is becoming increasingly evident that the complex physiological
network of ABC transporters has a pivotal role in host
detoxification and protection of the body against xenobiotics.
Among the human ABC superfamily, only ABCB1, ABCC1
(MDR1) and ABCG2 have to date been shown to mediate MDR,
each with distinct overlapping efflux substrate specificities and
tissue distribution patterns [3]. Fulfilling their role in detoxifica-
tion, several ABC transporters have been found to be over-
expressed in cancer cell lines cultured under selective pressure. In
particular, ABCB5 is overexpressed in melanoma, and ABCG2 is
expressed by a subcellular CD133-positive melanoma cells [4,5].
In this report, we investigated a new candidate for a melanoma
cancer stem cell (MCSC) marker, the cytokine co-receptor
CXCR6, with respect to the properties of ABCG2-expressing
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MCSCs. An important unresolved question in the field of cancer
stem cell (CSC) research is whether there is a direct lineage
relationship between CSCs and tissue-specific stem cells (TSSCs)
found in the normal tissues from which cancers arise. It is
worthwhile to identify markers that distinguish between tumori-
genic from non tumorigenic cells [6]. CD133 is expressed by most of
melanoma cell lines [4], and it does not seem able to distinguish
tumorigenic from non -tumorigenic cells [6]. Moreover recently,
Weissman’s group confirmed the presence of a more aggressive
subpopulation CD217+ in human melanoma [8]. We set out to
shed experimental light on this issue by investigating previously
described melanoma CSCs associated with established melanoma
cell lines [4,6] for evidence of asymmetric self-renewal, a specific
property of TSSCs [7,9]. For this evaluation, we employed a new
biomarker that we show here to be associated with asymmetric self-
renewal, the chemokine receptor CXCR6. In earlier studies,
CXCR6 was identified as a co-receptor for human immunodefi-
ciency virus infection of lymphocytes [10]. Low levels of CXCR6
expression have also been detected specifically on memory/effector
Th1 cells in peripheral blood [11]. More recently, expression of
CXCR6 was associated with human tumors, including melanoma
[12–14]. Herein, we show, based on studies with mouse cell lines
genetically engineered to undergo asymmetric self-renewal like
TSSCs, that both the pattern and level of CXCR6 expression is
specifically associated with asymmetric self-renewal division.
We looked for co-association of CXCR6 expression and
ABCG2 expression with MCSC activity and evidence for the
descent of melanoma CSCs from TSSCs. In fact, we find that a
large percentage of ABCG2-positive melanoma cells with known
CSC properties, also express CXCR6. Moreover, like ABCG2-
expressing melanoma cells, CXCR6-expressing cells are a small
fraction of cells in cultures of primary, metastatic melanoma cell
lines and human melanoma biopsy specimens. In vivo CXCR6+
melanoma cells produced a tumor in less time than ABCG2+ cells
and, more interestingly, the negative subpopulation did not give a
tumor. This phenotypic co-association of CXCR6, a biomarker
for asymmetric self-renewal in non-cancerous cells, with CSC
activity in tumor-derived cells is evidence for a direct lineage
relationship between TSSCs and CSCs in the case of melanocytic
cells and melanoma, respectively.
Finally, we have characterized the subpopulation ABCG2+/
ABCG2- and CXCR6+/CXCR6- of melanoma for the expression
of melanoma associated antigens (MAA) in view of a possible
immunotherapeutic approach against more aggressive subpopula-
tions expressing ABCG2 and/or CXCR6.
Results
Identification of CXCR6 as a biomarker for asymmetric
self-renewal division
Previously, we have reported studies with a genetically
engineered cultured cell model that provides experimentally
controlled asymmetric self-renewal divisions similar to those of
TSSCs [15,16,17]. The cells contain a Zn-regulated wild-type p53
cDNA gene. In Zn-free medium, these cells divide with symmetric
cell kinetics, producing two cycling cells from each division. These
divisions model symmetric TSSC divisions in which two stem cells
are produced. In ZnCl2-supplemented culture medium, conse-
quent normal levels of p53 expression induce asymmetric self-
renewal divisions that are characterized by divisions that produce
one cycling sister and one sister that arrests at G1/S. These
divisions model asymmetric TSSC divisions that produce one stem
cell and one cell that either differentiates or serves as the
progenitor for a differentiating cell lineage.
In gene micro-array analyses (NCBI-GEOdata base, http://www.
ncbi.nlm.nih.gov/geo/query/acc.cgi?token=dlmlzmuowumsqxy&
acc=GSE25334), Cxcr6 was identified as a gene whose expression
was undetectable in symmetrically self-renewing congenic p53-null
control cells grown in ZnCl2-supplemented medium. However, it
was induced in p53-inducible cells undergoing asymmetric self-
renewal under the same culture conditions. Quantitative RT-PCR
analyses revealed that symmetrically self-renewing cells did express
Cxcr6 mRNA at a detectable level; but its expression increased
8.664.4 fold (n= 6 analyses; p = 0.002) in cells induced to shift to
asymmetric self-renewal.
The initial micro-array analyses also showed that asymmetric
self-renewal was obligatory for the increase in Cxcr6 expression;
and thereby indicated that the increased expression was not due to
p53 expression alone. Cxcr6 expression was also undetectable in
congenic p53-inducible cells genetically engineered with forced
expression of the type II inosine monophosphate dehydrogenase
gene (IMPDH II), even when p53 expression was induced.
Expression of IMPDH II, the rate-limiting enzyme for cellular
guanine ribonucleotide biosynthesis, prevents p53-induced asym-
metric self-renewal, while leaving p53-dependent gene regulation
intact [16,18,19]. By this criterion, Cxcr6 was defined as a specific
‘‘asymmetric self-renewal associated (ASRA)’’ gene.
To investigate the ASRA biomarker properties of CXCR6
protein, we examined its pattern of expression determined by
indirect in situ immunofluorescence (ISIF) detection in two related
single-cell self-renewal pattern assays. In the first, the sister pair
assay (SP; [19]), cells are plated at a sufficiently low density to
allow delineation of sister cells by their relatively closer proximity
after division. In the second, cells are analyzed after division in the
presence of cytochalasin D (CD; [20]). CD prevents cytokinesis,
but does not prevent nuclear division. The binucleated cells
thereby produced provide a more confident comparison of sister
nuclei.
In previous applications of the SP (previously called ‘‘daughter
pair;’’ [19] and CD assays, bromodeoxyuridine (BrdU) incorpo-
ration was used as a marker for cycling S phase cells. For the
present studies, we used the cell cycle phase-specific protein cyclin
A as an indicator of cycling cells. Cyclin A is a well-described
marker of cycling cells that increases progressively in level from
late G1 phase to G2 phase of the cell cycle [21]. The
epifluorescence micrographs in Fig. 1 show how indirect ISIF
can be employed in SP and CD assays to distinguish asymmet-
rically self-renewing cells (ASYM) from symmetrically renewing
ones (SYM). Under conditions that foster symmetric self-renewal,
sister cell pairs and CD-arrested binucleated cells show a high
frequency of symmetric cyclin A detection. In contrast, under
conditions that foster asymmetric self-renewal, an asymmetric
pattern of cyclin A expression is significantly more frequent.
As shown in Fig. 1, CXCR6 protein is detected in both the
cytoplasm and nucleus of the genetically engineered cells used to
identify CXCR6 as an ASRA biomarker. The level of nuclear
expression is higher in cells under conditions of asymmetric self-
renewal, consistent with the mRNA expression data, which was
described earlier. In both SP and CD analyses, under conditions of
symmetric self-renewal, CXCR6 protein is detected in both nuclei
of sister cells. In contrast, under conditions that promote
asymmetric self-renewal, cells show a higher frequency of the
asymmetric expression pattern that is also directly correlated with
the asymmetric pattern of cyclin A. In quantitative CD analyses,
under conditions for symmetric self-renewal, only 6% of
binucleated cells showed coordinate asymmetric expression of
cyclin A and CXCR6; whereas 27% showed this specific pattern
under conditions for asymmetric self-renewal (p = 0.001). These
CXCR6 Asymmetric Self Renewal and CSCs Marker
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findings identify CXCR6 as a first-described up-regulated
biomarker of cells undergoing asymmetric self-renewal like
TSSCs.
ABCG2 and melanoma formation
In a recent paper, our group published that ABCG2 is
expressed by a subpopulation of human melanoma cells (cell line
WM115) expressing high level of CD133 [4]. We extended this
analysis of ABCG2 to two additional melanoma cell lines derived
from the same melanoma patient: primary melanoma cell line
IGR39 and the related metastatic line IGR37.
First, as shown in Table 1, we analyzed three polymorphisms
C/A (421 C.A), C/T (S248T) and C/T (F208S) in the unsorted
populations and in the ABCG2+ and ABCG2- sorted subpopu-
lations revealing a heterozygous status of ABCG2 for all the three
polymorphisms. These results are consistent with the origin of the
cell lines from the same patient. We focused on these
polymorphisms since SNP 421C.A is most common between
different ethnic groups [22] and has been associated with
decreased expression of the ABCG2 protein [23]. Moreover,
F208S and S248P polymorphisms were associated with defective
active transport of methotrexate and haematoporphyrin [24]; and,
in particular, F208S variant proteins (both-glycosylated and
immature forms) are recognized as misfolded proteins by putative
‘‘check point’’ systems and readily undergo ubiquination and
protein degradation in proteasomes [25].
Respectively, ,11% and ,40% of cells in actively growing
cultures of IGR37 and IGR39 had detectable expression for
ABCG2 (Fig. 2). IGR37 and IGR39 cells were sorted into
ABCG2+ and ABCG2- subpopulations and transplanted into
NOD-SCID mice (n = 3 for each subpopulation evaluated).
Unsorted cells were also injected into NOD-SCID mice (n = 3)
for comparison. After two months, mice from all cohorts were
sacrificed. Tumor masses were excised, imaged, weighed, and
digested to isolate single cell suspensions for further analysis. As
shown in Table 2 and Fig. 3, the transplantation of ABCG2+
IGR37 cells resulted in tumors with 2-fold greater mass on average
compared to tumors that arose from ABCG2- cells (p,0.01).
Interestingly, injection of unsorted IGR37 cells also result in
smaller tumors than ABCG2+ cells that were statistically similar in
sizes to tumors from ABCG2- cells (Fig. 3; Table 2). Unsorted
IGR39 cells resulted in smaller tumor masses, compared to
Figure 1. Demonstration of the asymmetric self-renewal associated (ASRA) biomarker properties of CXCR6. Shown are examples of
epifluorescence and phase contrast micrographs from parallel SP and CD analyses, as described in the text. SYM, symmetric self-renewal (Congenic
p53-null engineered cell lines grown in ZnCl2-supplemented medium). ASYM, asymmetric self-renewal (Zn-dependent, p53-inducible engineered
cells grown in ZnCl2-supplemented medium). DNA, DAPI nuclear DNA fluorescence. CyA, indirect ISIF with specific antibodies for cyclin A. CXCR6,
indirect ISIF with specific antibodies for CXCR6. Note that in the ASYM state, CXCR6 is up-regulated in the cycling cell, which models asymmetrically
self-renewing TSSCs. Phase, phase contrast micrograph. Scale bar =50 microns.
doi:10.1371/journal.pone.0015183.g001
Table 1. Analysis of ABCG2 polymorphisms.
Cells 421 C.A (C/A) S248P (C/T) F208S (C/T)
IGR37 CA CT CT
IGR39 CA CT CT
ABCG2+ IGR37 CA CT CT
ABCG2- IGR37 CA CT CT
ABCG2+ IGR39 CA CT CT
ABCG2- IGR39 CA CT CT
doi:10.1371/journal.pone.0015183.t001
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unsorted IGR37 cells (0.13 grams vs. 1.4 grams, respectively;
p,0.01) 2 months after the injection of the cells (Table 1).
ABCG2- sorted IGR39 cells did not exhibit any macroscopic
masses at this timepoint (Table 2), while ABCG2+ IGR39 cells
produced tumors with a 3.6-fold increased mass compared to
unsorted IGR39 cells (Table 2; p,0.01).
Single cell suspensions were obtained from all tumor xenografts
and analyzed after one to two passage by means of flow cytometry
to detect ABCG2-expressing cells. Consistent with previous
observations with WM115 human melanoma cells and melanoma
biopsies [4], ABCG2 expression was undetectable in all the tumor
xenograft cell preparations (data not shown).
CXCR6 and melanoma formation
IGR37 and IGR39 cell populations exhibited 10.6% and 9.6%
frequencies of expression for CXCR6, respectively (Fig. 4).
CXCR6+ and CXCR6- subpopulations of IGR37 and IGR39
cells were sorted and injected into NOD-SCID mice (n = 3 mice
per cohort), as was done for cells sorted on the basis of ABCG2
expression. Surprisingly, as shown in Fig. 5 and Table 2, after only
21 days from the injection of CXCR6+ IGR37 cells, significant
tumors appeared that were on average 1.8-fold greater in mass
than tumors that arose from unsorted IGR37 cells (p,0.01).
Moreover, no tumors were detected from CXCR6- injected cells
(Table 2 and Figure 6) after even 2 months. Furthermore, the
CXCR6- cells did not show any mass even after 4 months. Similar
results were obtained for IGR39 cells. CXCR6+ cells produced
tumors with 2.5-fold greater mass compared to unsorted cells; and
no mass was detected for the CXCR6- cells (Table 2). As for
ABCG2, CXCR6+ cells were also undetectable in tumor
xenografts by flow cytometry (data not shown).
Finally, we analyzed the percentage of CXCR6+/ABCG2+
double-positive cells for both cell lines. As shown in Fig. 7, 6.7%
and 3.1% of IGR37 and IGR39 cells, respectively, were double-
Figure 2. Flow cytometry detection and sorting of ABCG2+ subpopulations from cultures of human melanoma cell lines. Primary
melanoma IGR39 cells and metastatic melanoma IGR37 cells were incubated with the indicated fluorescent FITC-conjugated antibodies and analyzed
by flow cytometry as described in Materials and Methods. Y-axes, side scatter; x-axes, relative fluorescence intensity. Left panels, analyses with
isotype (IgG) control antibodies; middle panels, analyses with anti-ABCG2 FITC-conjugated antibodies. After FACS isolation based on the indicated
gate (blue outline), ABCG2+ sorted cells were reanalyzed to confirm enrichment (right panels). Numbers, percent of total evaluated cells.
doi:10.1371/journal.pone.0015183.g002
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positive for ABCG2 and CXCR6. When we injected ABCG2+/
CXCR6+ double positive IGR39 cells into NOD-SCID mice,
tumors arose that had on average 4-fold greater mass compared to
tumors developed from unsorted cells (p,0.01; Table 2). Like
IGR39 cells sorted based on CXCR6 expression alone, tumors
from IGR39 ABCG2+/CXCR6+ cells required only 21 days for
tumor detection (Table 2).
Melanoma phenotype of tumor xenografts
The multiparametric immunohistochemical analysis of
ABCG2+ IGR37 cells xenografts (Table 3 and Figure 8) revealed
that the tumor originating from these cells displayed an
homogenous expression of the differentiation antigens HBM45,
HMW-MAA, and of the endothelin B receptor, and an
heterogenous expression of the Melan-A antigen. No specific
staining for the ET-1 peptide could be documented. All cell
associated progression antigens evaluated were homogenously
expressed. The extracellular matrix macromolecule tenascin was
detected in the tumor graft as an extensive interstitial network
entrapping cell nests of variable size. Among the foetal antigens
analyzed, no detectable levels of NY-ESO were found while a
weak expression of MAGE antigens was observed. Similar results
have been obtained for ABCG2+IGR39 cells (data not shown).
The CXCR6+/ABCG2+ phenotype in human melanoma
biopsies
Although the evaluated melanoma cell lines were derived from
human tumor tissues, the newly described CXCR6+/ABCG2+
cell phenotype might have been limited to cultured tumor cells.
Therefore, we investigated 4 uncultured human melanoma
positive lymph node biopsy specimens for the presence of cells
with the CXCR6+/ABCG2+ phenotype. All the four biopsy
speciments contained a small subpopulation of cells ABCG2+
(12,2%, 8,4%, 2,65%, .0,1%). One of these three also contained
a small population CXCR6+ (0.25%) and a small population
double positive ABCG2+/CXCR6+ (0,3%). Fig. 9 shows the
Table 2. Mean tumor weight 6 SD (n = 3).
Cell line Mean±SD Time after injection
IGR39 Unsorted 0.1360.01 60 days
IGR39 ABCG2+ 0.4760.01* 60 days
IGR39 ABCG2- no mass 60 days
IGR39 CXCR6+ 0.3360.01* 21 days
IGR39 CXCR6- no mass 21 days
IGR39 AB/CX 0.5360.01 21 days
IGR37 Unsorted 1.460.3 60 days
IGR37 ABCG2+ 2.560.3* 60 days
IGR37 ABCG2- 1.260.2 60 days
IGR37 CXCR6+ 2.560.2* 21 days
IGR37 CXCR6- no mass 21 days
doi:10.1371/journal.pone.0015183.t002
Figure 3. Tumor xenografts derived from ABCG2+ and ABCG2- IGR39 cells. 56105 unsorted, ABCG2+ or ABCG2- sorted cells were injected
subcutaneously in five-week-old NOD-SCID mice (3 mice for each experimental condition). After 60 days, the tumor mass was excised weighed and
photographed.
doi:10.1371/journal.pone.0015183.g003
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results of the flow cytometry analysis of the CXCR6+/ABCG2+
positive specimens.
CXCR6 function and CXCL16 levels in melanoma cell lines
In a recent paper, binding of CXCR6 by the cleaved soluble
fragment of its membrane-bound ligand CXCL16 (‘‘sCXCL16’’)
was shown to enhance the proliferation of carcinoma cell lines
[11]. We investigated the effects of the free sCXCL16 ligand on
growth of IGR37 and IGR39 cells.
The levels of CXCL16 in the medium by unsorted cells of both
cell lines and in corresponding CXCR6+ cells were assayed using
ELISA (Fig. 10). The level of CXCL16 detected was extremely low
(0.06 OD units 60.03, n= 8). No significant difference was
observed between the unsorted cell and CXCR6+ sorted cells after
3 days of culture (Fig. 8).
According to the described methods, both cell lines were
incubated with sCXCL16 for 4 or 7 day. At the end of the
incubation, the cells were trypsinized and counted. As shown in
Fig. 11, by day 7, both cell lines exhibited a significant increase
(p,0.01) that averaged 1.4-fold in cell number in response to
sCXCL16 addition.
Melanoma associated antigen (MAA) expression and
ABCG2 versus CXCR6 expression
The expression profile of MAA belonging to the Cancer Testis
Antigens (CTA) family (MAGE-A1, -A2, -A3, -A6, GAGE 1–2,
GAGE 1-6, SSX-2, SSX 1–5, and NY-ESO-1) and of HMW-
MAA was performed by RT-PCR. As shown in Table 4, similar
detection patterns for ABCG2+ and ABCG2- subpopulations were
observed for both cell lines. In addition, the treatment with the
DNA hypomethylating agent 5-aza-2’-deoxycytidine was able to
induce a de novo expression of MAGE-A3, MAGE-A4, GAGE 1-2,
GAGE 1-6 and SSX 1-5 in both ABCG2+ and ABCG2- IGR37
melanoma cells (Table 5).
With respect to CXCR6+ and CXCR6- cell subpopulations in
IGR37 and IGR39 cell populations, as well as the double-positive
Figure 4. Flow cytometry detection and sorting of CXCR6+ subpopulations from cultures of human melanoma cell lines. Single
marker CXCR6 analyses. Primary melanoma IGR39 cells and metastatic melanoma IGR37 cells were incubated with the indicated fluorescent APC-
conjugated antibodies and analyzed by flow cytometry as described in Materials and Methods. Y-axes, side scatter; x-axes, relative fluorescence
intensity. Left panels, analyses with isotype (IgG) control antibodies; middle panels, analyses with anti-CXCR6 APC-conjugated antibodies. After
FACS isolation based on the indicated gate (blue outline), CXCR6+ sorted cells were reanalyzed to confirm enrichment (right panels).
doi:10.1371/journal.pone.0015183.g004
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ABCG2+/CXCR6+ IGR37 cells, there was an overlap of the
CTA family and of HMW-MAA (Table 6). Furthermore, in the
CXCR6+ IGR37 tumor xenograft, all the MAA family proteins
overlapped with the exception of CXCR6+ IGR37 cells for
tyrosinase, Mart-1, and Gp100 (Table 6).
Discussion
A fundamental problem in cancer research is identifying the cell
type that is capable of sustaining neoplastic growth. There is
evidence that the majority of cancer cells are clones and that
cancer cells represent the progeny of a single cell (reviewed in [6]).
However it is unclear which cells possess the tumor-initiating cell
function, maintaining the tumor growth. The idea of cancer stem
cell theory is that specific cells (i.e., cancer stem cells, CSCs) possess
the required regenerative properties that lead to tumor formation
[6]. Another important point, up to now unclear, is the origin of
the putative CSCs [6]. An important way to demonstrate that a
specific subpopulation can sustain the tumor growth is to use
xenograft models for human cells or syngenic models for murine
cells. However, an important criticism about, in particular, the
xenograft model is that it is an artificial model, being, for instance,
in that heterologous environmental factors are not considered [6].
On the other hand, another crucial point is to identify the markers
that are able to define a cancer/initiating stem cell subpopulation.
In the present paper, we have identified a new biomarker which
is associated with asymmetric self-renewal, the chemokine co-
receptor CXCR6. In addition, to the role of CXCR6 in the
immune response [10,12], more recently, CXCR6 expression has
been reported in some human tumors, including melanoma [12].
Comparing two parental human melanoma cell lines, IGR39
(primary) and IGR37 (metastatic), the latter was more aggressive
for tumor xenograft formation compared to primary melanoma
IGR39 cells. This difference in tumorigenic potential was reflected
in the CXCR6-sorted subpopulations. Actually, CXCR6+ cells
resulted in larger tumor mass in a signficantly shorter time period,
as compared to unsorted cells. Furthermore, CXCR6- cells did not
result in any significant, observable tumor mass. Since CXCR6
expression was found to be linked to asymmetric self-renewal that
is typical of TSSCs, MCSCs seem to be derivative of tissue-specific
melanocyte stem cells. Although, it is postulated that asymmetric
self-renewal by TSSCs must be ablated for them to become tumor
precursors [9,15], such mutated cells may still maintain markers
associated with their previous capacity for asymmetric self-
renewal, even after this TSSCs function is altered by mutations.
Several ABC transporters have been found to be over-expressed
in cancer cell lines cultured under selective pressure [6]. In
particular, in regards to melanoma, ABCB5 is overexpressed in
melanoma and ABCG2 is expressed by a sub-fraction of CD133-
positive melanoma cell population [4,5]. Herein, we show, for the
first time, a relationship between ABCG2 and asymmetric self-
renewal. In fact, ABCG2+ cells gave a bigger tumor mass than
Figure 5. Tumor xenografts derived from CXCR6+ IGR37 cells. 56105 CXCR6+ sorted cells were injected subcutaneously in five-week-old
NOD-SCID mice (3 mice for each experimental condition). After 21 days, the tumor mass was excised weighed and photographed.
doi:10.1371/journal.pone.0015183.g005
Figure 6. Tumor xenografts derived from and CXCR6- IGR37
cells. 56105 CXCR6- sorted cells were injected subcutaneously in five-
week-old NOD-SCID mice (3 mice for each experimental condition).
CXCR6- cells did not yield tumors.
doi:10.1371/journal.pone.0015183.g006
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ABCG2- cells in immunodeficient mice. However, CXCR6-
expressing cells were more aggressive for tumor formation than
ABCG2-expressing cells, suggesting that the subpopulation
CXCR6+/ABCG2+ cells may be the most potent MCSCs.
On the other hand, an interesting question is why neither
ABCG2+ nor CXCR6+ cells were detected in tumor xenografts.
They might be too rare, or they might not receive the required
environmental input for expression in immunodeficient mice. In
Figure 7. Flow cytometry detection and sorting of CXCR6+ subpopulations from cultures of human melanoma cell lines. Dual marker
analyses for CXCR6 and ABCG2. Primary melanoma IGR39 cells and metastatic melanoma IGR37 cells were incubated with the indicated fluorescent
APC-conjugated antibodies and analyzed by flow cytometry as described in Materials and Methods. Left panels, bivariate fluorescence intensity
analyses with respective APC- and FITC-conjugated isotype (IgG) control antibodies; middle panels, bivariate fluorescence intensity analyses with
respective APC- and FITC-conjugated CXCR6-specific and ABCG2-specific antibodies. Numbers, percent of total evaluated cells.
doi:10.1371/journal.pone.0015183.g007
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fact, if we cultured tumors derived from ABCG2+ or CXCR6+
cells their expression returned in culture after one to two passages
[4] (data not shown). In this regard, it is important to emphasize
that our analysis of human melanoma biopsies confirmed the
presence of a ABCG2+/CXCR6+ subfraction in human tissues.
This finding is significant for ruling out the possibility that the
ABCG2+/CXCR6+ cell phenotype exists only in cell culture.
Thus, its seems more likely that expression of the proteins is
prevented by some unknown mechanism in immunodeficient
mice, or other species in general.
Targeting of MCSCs may present a novel and more effective
clinical approach for human melanoma treatment. However, their
specific antigen profile may hamper the clinical outcome of
immunotherapeutic strategies for these patients. In this context, we
investigated the extent MCSCs profile for specific tumor-
associated antigens (TAAs) currently utilized as therapeutic targets
in the clinical setting. Actually, the lack of the appropriate
therapeutic targets on MCSCs might in fact result in the long-term
resistance to treatment, sustained by the outgrowth of TAA-
negative melanoma cell clones. In this context, the emergence of
TAA-negative cells able to evade immune control has been
reported in melanoma patients undergoing immunological
treatment [26]. Cancer testis antigens (CTAs) encompassing large
families of methylation-regulated and strictly related TAAs, first
identified in human melanomas [27], represent the most
promising therapeutic targets currently utilized in melanoma
patients. Therefore, herein, we have addressed the following
question: Can TAAs, currently utilized as targets in melanoma
immunotherapeutic protocols, be used to target ABCG2-positive
or CXCR6-positive cells? For both ABCG2 and CXCR6, an
overlap in the expression profile of the investigated TAA and of
HMW-MAA was observed between positive and negative
subpopulation derived from the same parental cell cultures. In
addition, the treatment with the DNA hypomethylating agent 5-
aza- 2’-deoxycytidine was able to induce a de novo expression of
MAGE-A3, MAGE-A4, GAGE 1-2, GAGE 1-6 and SSX 1-5 in
both ABCG2+ and ABCG2- melanoma cells derived from the
same parental cell culture. Therefore, these data suggest the
potential clinical effectiveness of TAA-based immunotheraputic
strategies, alone or combined with DNA hypomethylating drugs,
for more effective eradication of MCSC and non-MCSC
neoplastic cells in patients with cutaneous melanoma. These
findings show that CXCR6 identifies a more discrete subpopula-
tion of cultured human melanoma cells with a more aggressive
melanoma cancer stem cell (MCSC) phenotype than cells selected
on the basis of ABCG2 expression. The fact that CXCR6 is a
biomarker for TSSC asymmetric self-renewal supports the
hypothesis that MCSCs originate for mutated melanocyte stem
cells. Targeting of MCSCs may present a novel and more effective
clinical approach for human melanoma treatment. However, their
specific antigen profile may hamper the clinical outcome of
immunotherapeutic strategies for these patients. In this context, we
investigated the extent MCSCs profile for specific tumor-
associated antigens (TAAs) currently utilized as therapeutic targets
in the clinical setting. For both ABCG2 and CXCR6, an overlap
in the expression profile of the investigated more promizing
therapeutic targets TAA was observed between positive and
negative subpopulation derived from the same parental cell
cultures [26].
Figure 8. Immunohistochemical analysis of ABCG+IGR37 tumor xenograft. The tumor cell population homogenously expresses Melan-A (A)
and the HMW-MAA (B) differentiation antigens. The same distribution characterizes the tumor progression antigens HER-3 (C) and the extracellular
macromolecule tenascin (D). The latter characteristically delimits tumor areas of variable size. (1606magnification).
doi:10.1371/journal.pone.0015183.g008
Table 3. Antigenic Phenotype of ABCG+ IGR37 xenograft as
detected immunohistochemistry.
Differentiation Antigens
Progression
antigens
Cancer testis
antigens
HMW-MAA positive CD9 positive NY-ESO-1 negative
HBM-45 positive c-met positive MAGE-A positive
Melan-A positive HER-3 positive
ET-Br positive Tanascin positive
ET-1 negative
doi:10.1371/journal.pone.0015183.t003
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Alltogether our findings have important implication for under-
standing the origin of cancer and the possible use of asymmetric self-
renewal biomarkers to target more aggressive cells.
Materials and Methods
Ethics statement
Mice were purchased from Chrales River (Charles River Lab,
Boston, MA) and housed in pathogen-free conditions at IFOM
(Milan) facility. Experiments and care/welfare were in agreement
with national regulations and an approved protocol by the IFOM
committee approved by the National ‘‘Ministero per la Ricerca’’
(ID: 2/2005).
Affymetrix oligonucleotide micro-array analysis
Whole genome expression profiles of p53-induced Ind-8 cells,
p53-null Con-3 cells, and p53-induced/IMPDH II-transfected tI-3
cells [15,16,17] were compared by analyzing Affymetrix mouse
Figure 9. Flow cytometry detection of CXCR6+/ABCG2+ subpopulations from human melanoma biopsy. Flow cytometry analysis of a
human melanoma biopsy specimen for a CXCR6+/ABCG2+ subfraction. A metastatic melanoma biopsy specimen was processed as described in
Material and Methods and immediately analyzed by flow cytometry. Left panel, bivariate fluorescence intensity analyses with respective APC- and
FITC-conjugated isotype (IgG) control antibodies. Right panel, bivariate fluorescence intensity analyses with respective APC- and FITC-conjugated
CXCR6-specific and ABCG2-specific antibodies. Numbers, percent of total evaluated cells.
doi:10.1371/journal.pone.0015183.g009
Figure 10. CXCL16 detection in growth medium of unsorted and sorted CXCR6+ IGR37 and IGR39 cells. 50,000 cell/well were plated in
24 multi-well plates. When the cells reached ,90% confluency (,3–4 days), medium was collected and briefly centrifuged. A 50 ml aliquot of
medium was used for CXCL16 detection using the Quantikine Human CXCL16 Immunoassay (R&D Systems, Minneapolis, MN). Bars represents the
mean 6 S.D. of three independent experiments each carried out in quintuplicate.
doi:10.1371/journal.pone.0015183.g010
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Figure 11. Evaluation of the effect of the CXCR6 ligand CXCL16 onmelanoma cell line growth. Twenty thousand cells were seeded overnight
in individual wells of 12 multi-well plates in complete medium growth condition. Recombinant sCXCL16 (100 ng/ml) was added the next day and replaced
every 48 hours. On the 4th and 7th day of culture, the cells were trypsinized, and viable cell numbers determined. The bar graph represents themean6 S.D.
of three independent experiments each carried out in triplicate. *, p,0.01 vs. untreated cells (black bars); **, p,0.001 vs. untreated cells (black bars).
doi:10.1371/journal.pone.0015183.g011
Table 4. RT-PCR analysis of Melanoma Associated Antigens (MAA) expressed by the melanoma cell cultures IGR37 and IGR39
unsorted and sorted for ABCG2 expression.
MAA IGR37 IGR37 ABCG2+ IGR37 ABCG2- IGR39 IGR39 ABCG2+ IGR39 ABCG2-
MAGE-A1 - - - - - -
MAGE-A2 +/- + +/- + + +
MAGE-A3 + + + - - -
MAGE-A4 - - - - - -
GAGE 1-2 - - - - - -
GAGE 1-6 - - - - - -
NY-ESO-1 - - - - - -
SSX-2 - - - - - -
SSX 1-5 - - - - - -
tyrosinase ++ ++ ++ - - -
MART-1 ++ + ++ - - -
gp100 ++ + ++ - - -
HMW-MAA + + + + + +
Intensity of RT-PCR products: -, not detectable; +/-, weak; +, positive; ++, strong positive.
doi:10.1371/journal.pone.0015183.t004
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whole genome GeneChipH 430 2.0 arrays (Affymetrix, Inc. Santa
Clara, CA). Three independent cell cultures for Ind-8 and Con-3
cells and two for tI-3 cells, which were quality-controlled for
respective asymmetric, symmetric, and symmetric self-renewal,
were used for RNA isolation. Total RNA samples were prepared
using the Trizol reagent (Invitrogen, Carlsbad, CA) and followed
by a clean-up step with the Qiagen RNeasy kit (Qiagen, Valencia,
CA). Total RNA quality was tested with the Agilent 2100
BioAnalyzer (Agilent Technologies, Palo Alto, CA). Five mg of
total RNA was used for cDNA synthesis, and the produced cDNA
was used to make biotinylated cRNA. cRNA was fragmented and
hybridized onto the Affymetrix mouse whole genome GeneChipH
430 2.0 array. The arrays were washed and quantified with a
fluorescence array scanner. After scanning the chips, quantifica-
tion and statistics were performed using model-based expression
and the perfect match (PM) minus mismatch (MM) method in the
G-COSH software (version 1.0) and/or the dChip software version
2005. Data across 8 arrays were normalized by setting target
intensity at 500 in the G-COS analysis. An exclusively expressed
gene set for asymmetric self-renewal was selected from probe sets
that were called a ‘present’ for all 3 independent Ind-8 cell
preparations and called as ‘absent’ in all independent preparations
of Con-3 cells (n = 3) and tI-3 cells (n = 2) by the PM/MM
statistical model in the G-COSH software. The converse analysis
Table 5. RT-PCR analysis of Melanoma Associated Antigens (MAA) expressed by melanoma cell line IGR39 sorted for its expression
of ABCG2 and then treated with 5-AZA-CdR.
CTA ABCG2+ ABCG2+ AZA 1 ABCG2+ AZA 10 ABCG2- ABCG2- AZA 1 ABCG2- AZA 10
MAGE-A1 - - - - - -
MAGE-A2 + + + + + +
MAGE-A3 - - +/- - - +/-
MAGE-A4 - - + - - +
MAGE-A10 + + + + + +
GAGE 1-2 - - + - - +
GAGE 1-6 - - + - - +
NY-ESO-1 - - + - - +
SSX-2 - - - - - -
SSX 1-5 - - + - - +
PRAME + + + + + +
Tyrosinase - - - - - -
MART-1 - - - - - -
Gp100 - - - - - -
Intensity of RT-PCR products: -, not detectable; +/-, weak; +, positive; ++, strong positive.
doi:10.1371/journal.pone.0015183.t005
Table 6. RT-PCR analysis of Melanoma Associated Antigens (MAA) expressed by melanoma cell lines IGR37 and IGR39 sorted for its
expression of CXCR6 and double positive ABCG2/CXCR6 IGR37 cells and in tumor xenograft engrafted with CXCR6+ IGR37 cells.
CTA IGR37CX+ IGR37CX- IGR37CX/AB+ IGR39CX+ IGR39CX-
MAGE-A1 - - - - -
MAGE-A2 + + + + +
MAGE-A3 +/- - - +/- -
MAGE-A4 - - - - -
GAGE 1-2 - - - - -
GAGE 1-6 - - - - -
NY-ESO-1 - - - - -
SSX-2 - - - - -
SSX 1-5 - - - - -
PRAME + + + + +
Tyrosinase + - + - -
MART-1 + - + - -
Gp100 + - + - -
HMW-MAA + + + + +
Intensity of RT-PCR products: -, not detectable; +/-, weak; +, positive; ++, strong positive.
doi:10.1371/journal.pone.0015183.t006
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was performed to identify a set of genes expressed exclusively
during symmetric self-renewal.
All data is MIAME compliant and that the raw data has been
deposited in a MIAME compliant database (E.g. ArrayExpress,
GEO), as detailed on the MGED Society website http://www.
mged.org/Workgroups/MIAME/miame.html.
Evaluation of CXCR6 detection pattern in cytology assays
for self-renewal pattern
Low cell density sister pair (SP) analysis. For low cell
density SP analyses, trypsinized cells (prepared as described above)
were plated at 500 cells/cm2 in 2-well LAB-TEKH chamber slides
in Zn-free medium (Nunc, Inc., Naperville, IL) to permit sister-
sister designation based on close relative proximity. Five hours later,
the culture medium were replaced with either Zn-free medium or
medium supplemented to 65 M ZnCl2 to induce asymmetric self-
renewal. Twenty hours later, to allow for formation and cell cycle
progression of sister cells, slides were washed with ice-cold
phosphate buffered saline (PBS) and immediately fixed for 15
minutes at room temperature in PBS containing 3.7%
formaldehyde. After three washes in PBS, the cells were
permeabilized with 0.2% Triton X-100 (v/v in PBS) at room
temperature for 10 minutes and afterwards washed once with PBS.
Thereafter, cells were blocked with PBS containing 10% goat serum
for 1 hour at room temperature. They were then incubated
overnight at 4uC in a humidified chamber with an anti-mouse
cyclin A monoclonal antibody (Abcam, Inc., Cambridge, UK)
diluted 1:100 in PBS containing 2% goat serum. After five rinses in
PBS containing 0.5% bovine serum albumin (BSA), the cells were
incubated for 1 hour at room temperature with Alexa FluorH 568-
conjugated goat anti-mouse IgG (Invitrogen, Inc., Carlsbad, CA),
diluted 1:300 in the blocking solution. Next, the cells were washed
five times with PBS containing 0.5% BSA. For dual indirect ISIF (in
situ immunofluorescence) analysis, cells stained for cyclin A
detection were subsequently incubated in the same manner with
anti-rat CXCR6 monoclonal antibody (R&D Systems, Inc.,
Minneapolis, MN) at a 1:50 dilution followed by Alexa FluorH
488-conjugated goat anti-rat IgG (Invitrogen, Inc., Carlsbad, CA)
diluted 1:300. After washing, the cells were mounted with 4’-6-
diamido-2-phenylindole (DAPI)-containing VectaShieldHmounting
media (Vector Laboratories, Inc., Burlingame, CA).
Epifluroescence images were captured with a Leica DMR
microscope and Leica DC300F digital camera system. Pair-wise
control analyses that omitted anti-cyclin A and anti-CXCR6
antibodies separately and together were evaluated to ensure that
all detected fluorescence required these specific antibodies.
High cell density cytochalasin D (CD) analysis. For high
density binucleated cell analysis by cytochalasin D treatment, cells
were plated at 2,000 cells/cm2 in 2-well LAB-TEKH chamber
slides (Nunc, Inc., Naperville, IL). Thereafter cells were
maintained as for SP analyses except, before fixation, they were
treated with their respective media supplemented with 2 mM
cytochalasin D (Sigma-Aldrich Co., St. Louis, Mo) for 14 hours to
induce binucleated cell formation. The cells were then washed
with ice cold PBS and immediately fixed for 15 minutes at room
temperature in PBS containing 3.7% formaldehyde. Thereafter,
dual indirect ISIF analyses were performed for cyclin A and
CXCR6 as described above for SP analyses.
Cell lines
Genetically engineered mouse embryonic fibroblasts (MEFs)
that display TSSC asymmetric self-renewal in response to Zn-
induced expression of wild-type p53 (Ind-8 cells) and congenic
control vector-transfected, p53-null MEFs (Con-3 cells) were used
for self-renewal pattern evaluations according to Rambhatla et al.
[15]. Human IGR39 and IGR37 cells were obtained from
Deutsche Sammlung von Mikroorganismen und Zellkulturen
GmbH. IGR39 was derived from a primary amelanotic cutaneous
tumor and IGR37 was derived from an inguinal lymph node
metastasis in the same patient. The karyotype of IGR39 was tetra-
pentaploid and IGR37 11% polyploidy, both showing the same
rearrangements as der(1)t(1;21)(p13;q11)der(16)t(p13;q23) accord-
ing to Deutsche Sammlung von Mikroorganismen und Zellk-
ulturen GmbH. Both lines were cultured in DMEM, 15% FBS
supplemented with 1% MEM vitamin, 1% MEM aminoacid, 1%
antibiotics (Penicillin/Streptomycin), 1% L-glutamine (complete
medium) at 37uC in a 5% CO2 humidified environment.
Tumor formation analyses and isolation of single cells
from melanoma biopsy
56105 cells were injected subcutaneously into five-week-old
NOD-SCID mice (Charles River Laboratories, Boston, MA).
Animals were maintained on standard laboratory food ad libitum
fed and free access to water.
Melanoma biopsy (four) was obtained from National Italian
Institute of Tumor of Milan, Italy, after received approval from
the appropriate local Institutional Review Board. Tumor mass or
biopsy was excised and digested with 0.2% collagenase type I
(Gibco), 0.2% bovine serum albumin (BSA; SIGMA, St. Louis,
MO) for 30 minutes at 37uC on an orbital shaker.
Flow Cytometry
Cells were analyzed for fluoroscein isothiocyanate (FITC)
mouse anti-human ABCG2 (R&D Systems, Minneapolis, MN)
and allophycocyanin (APC) mouse anti-human CXCR6 (R&D
Systems, Minneapolis, MN) expression. All samples were analyzed
using one- or two-color flow cytometry with non-specific mouse
IgG used (Invitrogen, Carlsbad, CA) as isotype controls. For each
flow cytometry evaluation, a minimum of 56105 cells were stained
and at least 50,000 events were collected and analyzed (106 cells
were stained for sorting). Flow cytometry sorting and analysis was
performed using a FACSAriaTM flow cytometer (Becton, Dick-
inson and Company, BD, Mountain View, CA). Data were
analyzed using FlowJo software (Tree Star, Inc., San Carlos, CA).
SNP analysis
DNA was extracted from cells using a salting-out method [28]
Genotyping for ABCG2 421 C.A (assay ID: C__15854163_70),
S248P (assay ID: C__27458615_40) and F208S (assay ID:
C__8826940_10) single nucleotide polymorphisms (SNPs) were
performed using Validated TaqMan Genotyping Assay (Applied
Biosystems). PCR reactions were carried out as follows: initial
denaturation at 95uC for 10 min and 50 cycles of denaturation at
92uC for 15 seconds followed by anneal/extension at 60uC for 90
seconds. The software Opticon Monitor 2 was used in the analysis
(Celbio, Italy).
Effect of CXCL16 on cell proliferation
20,000 cells/well were seeded overnight in 12 multi-well plates
in complete medium and incubated with 100 ng/ml recombinant
sCXCL16 (PeproTech, Location) [12]. Live cell counts were
obtained using a Vi-CELLTM Automated Cell Viability Analyzer
(Beckman Coulter, Brea, CA, USA).
Detection of CXCL16 released by cells by ELISA
50,000 cell/well were plated in 24 multi-well plates and 50 ml
medium used for CXCL16 detection using the Quantikine
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Human CXCL16 Immunoassay (R&D Systems, Minneapolis,
MN).
Immunohistochemistry
Tumor xenografts were snap-frozen in liquid nitrogen and kept
at 270uC until processing. Four-micron cryostat sections were
fixed in absolute cold acetone for 10 minutes Indirect immuno-
peroxidase staining employed the following murine monoclonal
antibodies recognizing the indicated antigens: class I MHC
antigens (clone W6/32; American Tissue Type Collection,
USA), melanoma high molecular weight antigen (HMWA: clone
Ep.1; Miltenji Biotec, Germany), melanosome (clone HBM-45;
DakoCytomation, Denmark), Melan-A (clone A103; DakoCyto-
mation, Denmark), CD9 (clone P1/33/2; Santa Cruz Biotech,
Table 7. Primers and thermal protocols utilized for the RT-PCR evaluation of CTA and differentiation antigens expression in human
melanoma cells.
RT-PCR primers
Gene Sequence
Amplicon
length Thermal cycle
MAGE-A1 Sense CGGCCGAAGGAACCTGACCCAG 421 bp 30 cycles of 94uC 1 min, 72uC 3 min
Antisense GCTGGAACCCTCACTGGGTTGCC
MAGE-A2 Sense AAGTAGGACCCGAGGCACTG 230 bp 30 cycles of 94uC 1 min, 67uC 2 min,
72uC 2 min
Antisense GAAGAGGAAGAAGCGGTCTG
MAGE-A3 Sense TGGAGGACCAGAGGCCCCC 725 bp 30 cycles of 94uC 1 min, 72uC 4 min
Antisense GGACGATTATCAGGAGGCCTGC
MAGE-A4 Sense GAGCAGACAGGCCAACCG 446 bp 30 cycles of 94uC 1 min, 68uC 2 min,
72uC 2 min
Antisense AAGGACTCTGCGTCAGGC
GAGE 1-2 Sense GACCAAGACGCTACGTAG 201 bp 30 cycles of 94uC 1 min, 55uC 2 min,
72u 3 min
Antisense CCATCAGGACCATCTTCA
GAGE 1-6 Sense GCGGCCCGAGCAGTTCA 239 bp 30 cycles of 94uC 1 min, 56uC 2 min,
72u 3 min
Antisense CCATCAGGACCATCTTCA
NY-ESO-1 Sense CACACAGGATCCATGGATGCTGCAGATGCGG 379 bp 35 cycles of 94uC 1 min, 59uC 1 min,
72uC 1 min
Antisense CACACAAAGCTTGGCTTAGCGCCTCTGCCCTG
SSX 2 Sense GTGCTCAAATACCAGAGAAGATC 434 bp 35 cycles of 95uC 30 s, 65uC 30 s, 72u
1 min
Antisense TTTTGGGTCCAGATCTCTCGTG
SSX 1-5 Sense ACGGATCCCGTGCCATGAACGGAGACGAC 663 bp 35 cycles of 95uC 1 min, 67uC 1 min,
72u 2 min
Antisense TTGTCGACAGCCATGCCCATGTTCGTGA
PRAME Sense CTGTACTCATTTCCAGAGCCAGA 562 bp 30 cycles of 94uC 1 min, 63uC 2 min,
72uC 3 min
Antisense TATTGAGAGGGGTTTCCAAGGGGTT
Tyrosinase Sense TTGGCAGATTGTCTGTAGCC 284 bp 36 cycles of 94uC 30 s, 60uC 1 min,
72uC 1 min
Antisense AGGCATTGTGCATGCTGCTT
MART-1 Sense CTGACCCTACAAGATGCCAAGAG 602 bp 24 cycles of 94uC 1 min, 60uC 1 min,
72uC 1 min
Antisense ATCATGCATTGCAACATTTATTGATGGAG
GP100 Sense TATTGAAAGTGCCGAGATCC 361 bp 30 cycles of 94uC 1 min, 60uC 30 s,
72uC 1 min
Antisense TGCAAGGACCACAGCCATC
HMW-MAA Sense CAGCAGCTCCGGGTGGTTTCAGAT 623 bp 30 cycles of 94uC 40 s, 56uC 40 s,
72uC 1 min
Antisense GTAGGGCCGGGCAGCATTGTAAGG
b-actin Sense GGCATCGTGATGGACTCCG 615 bp 21 cycles of 94uC 1 min, 68uC 2 min,
72uC 2 min
Antisense GCTGGAAGGTGGACAGCGA
doi:10.1371/journal.pone.0015183.t007
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USA), Her-3 (kindly provided by Dr A. Ullrich), c-met (clone SC-
10; Santa Cruz, USA) tenascin (kindly provided by Dr. F.
Malavasi), murine monoclonal antibodies to Multi-Mage-A (clone
6C1) and NY-ESO-1 (Santa Cruz, USA) cancer testis antigens
(Santa Cruz, USA), endothelin B receptor (clone 39960; abcam
ab., UK), and endothelin-1 (clone TR-ET.5; Affinity Bioreagents,
USA). Working concentrations of the antibody were established on
selected positive controls (cell lines and tumor biopsies) available in
the laboratory. Staining was performed using the M.O.M.
immunodetection kit (mouse primary antibodies) or Vectastain
Elite ABC-Peroxidase kit (rabbit primary antibodies; Vector Lab.
Burlingame, CA, USA) following the manufacturer’s instructions.
Nuclear counterstain employed Mayer’s hematoxylin. Pictures
were taken using a Leitz Orthoplan microscope.
RT-PCR
Cxcr6 analyses. To validate the micro-array data, Q-RT-
PCR was performed with the TaqManH gene expression assay kit
(Applied Biosystems, Foster City, CA). The kit consists of a
FAMTM dye-labeled TaqManH MGB probe and primers for
detecting Cxcr6 (Mm00472858_m1) mRNA. The expression of
Cxcr6 was normalized against the expression level of
glyceraldehyde-3-phosphate dehydrogenase (Gapdh). One mg of
total RNA from p53-induced asymmetrically self-renewing Ind-8
cells and p53-null symmetrically dividing Con-3 cells was used for
reverse transcribing cDNA with the Superscript Reverse
Transcriptase (RT) II kit (Invitrogen, Carlsbad, CA). The cDNA
from the reverse transcription reaction was amplified by PCR to
measure the FAM fluorescence of each PCR cycle using the
Applied Biosystems 7700 Sequence Detection System. The
reactions were performed using the manufacturer’s instruction
after adjusting the reaction volume as 25 ml.
Tumor-associated antigens analyses. Total RNA
extraction and reverse transcription (RT)-PCR reactions were
done as previously described [29]. The oligonucleotide primer
sequences and gene-specific PCR amplification programs used are
reported in Table 7. The integrity of each RNA and
oligodeoxythymidylic acid-synthesized cDNA sample was
confirmed by the amplification of the b-actin housekeeping gene
[29]. Ten microliter of each RT-PCR sample was run on a 2%
agarose gel and visualized by ethidium bromide staining. The level
of expression of each gene was scored accordingly to the intensity
of the specific RT-PCR product, which was obtained by
densitometric analysis of ethidium bromide-stained agarose gels
using a Gel Doc 2000 documentation system and the
QuantityOne densitometric analysis software (Bio-Rad, Milan,
Italy). Samples were scored -, no RT-PCR product detectable; +,
expression level #10% to that of the appropriate reference cell
line; and ++ expression level .10% to that of the appropriate
reference cell line.
Real-time quantitative RT-PCR analysis
Real-time quantitative RT-PCR analyses were performed as
described [30]. Briefly, total RNA was digested with RNAse free
DNAse (Roche Diagnostics, Milan, Italy) to remove contaminating
genomic DNA. Synthesis of cDNA was performed on 1 mg total
RNA using MMLV reverse transcriptase (Invitrogen, Milan, Italy)
and random hexamer primers (Promega, Milan, Italy), following
manufacturers’ instructions. TaqMan quantitative PCR reactions
were performed on 20 ng retrotranscribed total RNA in a final
volume of 25 ml 1X TaqMan Universal Master Mix (Applyed
Biosystems, Milan, Italy). TaqMan primers/probe sets were as
follows: b-actin forward, CGAGCGCGGCTACAGCTT; b-actin
reverse, CCTTAATGTCACGCACGATT; b-actin probe, FAM-
ACCACCACGGCCGAGCGG-BHQ1; MAGE-A3 forward, TG-
TCGTCGGAAATTGGCAGTAT, MAGE-A3 reverse, CAAA-
GACCAGCTGCAAGGAACT; MAGE-A3 probe, FAM-TCTT-
TCCTGTGATCTTC-MGB. Real-time measurement of fluores-
cent signals was performed utilizing the ABI PRISM 7000 Sequence
Detection System (Applyed Biosystems) and the copy number of
MAGE-A3 and of the reference gene beta-actin was established in
each sample by extrapolation of a standard curve. The number of
MAGE-A3 cDNAmolecules in each sample was then normalized to
the number of cDNA molecules of b-actin.
Statistical analyses
Student’s t-test was used to estimate the statistical confidence for
differences in the weight of tumor masses that arose after the
transplantation of different classes of sorted and unsorted cells.
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